Reader-exclusive · 10% off DoNotAge Pure NMN Supplement on DoNotAge CODE BB10
DoNotAge Pure NMN Supplement 366-capsule bottle containing 500 mg β-NMN per capsule

DoNotAge · NMN catalogue · Physician-reviewed · #1 NMN pick

DoNotAge Pure NMN Review — Uthever® β-NMN, 500 mg per Capsule or Scoop

RECOMMENDED Product Review13 min readLast verified 21 Sep 2026
4.9/5Our #1 NMN pick for 2026: Uthever® traceability, current CoA access, every-batch testing, simple filler-free formulation, flexible 500 mg dosing and a strong ingredient-to-human-research evidence chain.

What stands out

  • Uses Uthever® β-NMN, a named ingredient with a published randomized human trial rather than an anonymous NMN source
  • Single-active-ingredient formula makes dose, tolerability and evidence easier to interpret than multi-ingredient longevity stacks
  • 500 mg per capsule/scoop gives straightforward 500 mg or 1,000 mg daily dosing across capsule and powder formats
  • DoNotAge publishes its latest NMN Certificate of Analysis online and states that every batch is independently tested for purity and potency to a 99.8% standard

Things to know first

  • Like nearly every retail NMN supplement, the exact finished DoNotAge bottle does not have its own randomized outcomes trial; its evidence chain instead combines Uthever® ingredient research with finished-product testing.
  • The ingredient-specific Uthever® RCT used 300 mg/day, while DoNotAge offers flexible 500–1,000 mg daily use; the higher doses are supported by the broader NMN literature rather than that single branded-ingredient trial.

Key takeaways

  • DoNotAge Pure NMN currently provides 500 mg per capsule or scoop and identifies Uthever β-NMN as its source.
  • The 500 mg unit dose gives practical flexibility: one capsule/scoop matches a common modern NMN dose, while two provide the brand's 1,000 mg/day routine used within the broader range studied in human NMN research.
  • DoNotAge states every batch is independently tested to a 99.8% purity standard and currently provides NMN Certificate of Analysis documentation, strengthening the product's quality-control case.
  • Uthever® gives DoNotAge a useful ingredient-to-human-trial evidence chain that anonymous-source NMN products cannot offer.
  • Its single-ingredient, filler-free format makes DoNotAge Pure NMN easy to dose, audit and combine with a personalized longevity routine.

Bottom line

Our #1 NMN pick for 2026: a simple Uthever® β-NMN product with clear 500 mg dosing and credible quality-control claims. We recommend it for its sourcing and evidence architecture—not because NMN has proven human lifespan extension.

Our verdict

DoNotAge Pure NMN is our #1 NMN recommendation for 2026. It combines explicit Uthever® β-NMN sourcing, a simple filler-free formula, practical 500 mg unit dosing, current Certificate of Analysis access and a stated every-batch independent testing program. Uthever® also gives the product a traceable connection to published randomized human research. No retail NMN product has proven human lifespan extension, so our recommendation is based on product quality, traceability, formulation simplicity and the strength of the evidence chain rather than an anti-aging cure claim.

Re-checked September 21, 2026 against DoNotAge's current Pure NMN page, March 2026 NMN quality guidance and the 57-paper NMN Data Center. Current retail lot not independently assayed by Biohack Blueprint.
Reader-exclusive

DoNotAge Pure NMN Supplement — via DoNotAge

Use code 10% off
  • 14-day money-back guarantee
  • 183 days at 1,000 mg/day for the 366-capsule bottle; other capsule and powder formats vary supply per bottle
  • Subscribe & save available
  • Fast shipping from DoNotAge
Get 10% off on DoNotAge with BB10 →

DoNotAge handles pricing, fulfilment, and customer support for this product. Biohack Blueprint may earn a commission from purchases made through links on this page, at no extra cost to you. This does not affect our evidence grading or editorial verdict.

Physician-authored Recommended #1 NMN Uthever® source NMN CoA access 57-paper Data Center Every-batch testing stated BB10 saves 10%

Who this is for

Good fit if you're...

You want a named NMN ingredient with a published human trial behind the raw material

DoNotAge explicitly identifies Uthever® β-NMN, whose 300 mg/day formulation has a published randomized human trial.

You prefer a single-ingredient NMN product rather than a longevity stack

Pure NMN keeps active-ingredient attribution simple and avoids charging for unproven combination synergy.

You want easy 500 mg or 1,000 mg daily dosing

Each capsule or scoop contains 500 mg, making common research-range doses straightforward.

You want the choice of capsules or powder

DoNotAge offers both formats while using the same core β-NMN ingredient source.

Probably not for you if...

You require an instantly visible lot-matched report before purchase

DoNotAge states every batch is tested and provides CoA access, but its current pages describe that access in two ways: the March 2026 NMN guidance says the latest CoA is online, while the product FAQ says certificates are available on request.

You are receiving active chemotherapy without oncology approval

Preclinical pancreatic-cancer work raises a treatment-specific caution around NMN during cytotoxic therapy.

You want a supplement proven to extend human lifespan

No NMN product has demonstrated human lifespan extension or generalized reversal of biological aging.

Key facts & composition

Active ingredient β-Nicotinamide mononucleotide (β-NMN) Uthever® branded NMN
Unit dose 500 mg per capsule or scoop Capsule and powder formats
Brand daily guidance 500–1,000 mg/day 1,000 mg/day is highlighted as the standard recommendation; higher Subscribe & Save options also exist
Ingredient source Uthever® NMN Named branded source with a 60-day human randomized trial at 300 mg/day
Quality control Every-batch testing + CoA access DoNotAge states every NMN batch is third-party tested to a 99.8% purity standard. Its March 2026 NMN guidance says the latest CoA is available on its website, while the current product FAQ says certificates are available on request.
Formats Capsules and powder Capsule shell is plant-based HPMC; powder is sold without added fillers
Ongoing clinical research DoNotAge.org collaborator on NCT06889142 Registered 1,000 mg/day NMN proof-of-concept study in HIV immunological non-responders; planned n=7, open-label, no results posted. The public registry names NMN generically rather than the retail Pure NMN bottle.

Composition

Ingredient Amount Form Source
β-Nicotinamide mononucleotide (NMN) 500 mg per capsule or scoop Uthever® β-NMN EffePharm / Uthever®

DoNotAge identifies Uthever® as its NMN source. Its capsule version uses a plant-based HPMC shell; the powder is marketed as NMN without added fillers. The published Uthever randomized trial used 300 mg/day for 60 days, and its efficacy comparisons versus placebo were not statistically significant. It therefore supports ingredient traceability and human exposure—not direct proof of DoNotAge's 1,000 mg/day finished product or broad clinical efficacy.

How it works

NMN is a precursor in the network that produces NAD+, a coenzyme central to redox metabolism and NAD-consuming signaling enzymes. Human supplementation consistently changes blood NAD-related biomarkers, but oral NMN undergoes gut and microbial processing and a higher NAD+ value does not automatically equal a clinical anti-aging benefit.

1

NMN feeds the NAD+ synthesis network

NMN sits directly upstream of NAD+ in the cellular salvage pathway. Human oral studies repeatedly show that NMN changes blood NAD-related pools, including the Uthever trial [1] and the larger 2026 direct precursor study [2]. That target engagement is the most reproducible human NMN finding.

2

Oral NMN is processed, not simply delivered intact to every tissue

Modern human and mechanistic work shows substantial gut and microbial processing of NMN before its components feed host NAD pathways [2]. That makes ordinary oral NMN biologically active without proving that one delivery-system claim is superior.

3

Higher NAD+ is target engagement, not automatic age reversal

The 2026 NMN meta-analysis found short-term safety broadly reassuring while many routine metabolic endpoints remained neutral [3]. Raising NAD+ therefore confirms biological activity, but it does not prove weight loss, cognitive enhancement or lifespan extension.

This review draws on 21 peer-reviewed papers indexed in our NMN Data Center →

The evidence

Claims below are graded A to F by the strength and consistency of the human evidence. The grade describes what NMN research can support—not whether the DoNotAge bottle contains authentic NMN. Product identity and clinical efficacy are separate questions.

A

Raises blood NAD+ or NAD-related metabolites

Tier 1

Repeated randomized human studies show oral NMN increases blood NAD+ or related metabolites across different doses and formulations, including Uthever [1], 2026 direct precursor data [2] and dose-ranging studies. This is NMN's most reproducible human effect.

Hao Huang 2022, Christen S et al. 2026, Keisuke Okabe et al. 2022, Lin Yi et al. 2023, Pencina KM et al. 2023

A

Generally well tolerated over short human trial durations

Tier 1

The 2026 NMN meta-analysis found no significant increase in overall adverse events, serious adverse events, withdrawals or liver-enzyme abnormalities [3]. EFSA also issued a favorable safety opinion for a specified β-NMN material under defined conditions, while multi-year safety remains unknown.

Wenyu Yang et al. 2026, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. 2026, Junichiro Irie et al. 2020, Yuichiro Fukamizu et al. 2022

B

May improve skeletal-muscle insulin sensitivity in selected prediabetic adults

Tier 1

A well-designed randomized trial in postmenopausal women with prediabetes improved skeletal-muscle insulin sensitivity [8]. Broader meta-analyses remain mostly neutral for fasting glucose, HbA1c and HOMA-IR, so this should not be generalized into a diabetes-treatment claim.

Mihoko Yoshino et al. 2021, Wenyu Yang et al. 2026, Feng Chen et al. 2024

B

May improve selected physical-function or aerobic-performance outcomes

Tier 2

Positive signals have appeared in dose-ranging, amateur-runner and older-adult trials, while the systematic evidence remains mixed [10]. NMN should not be presented as a proven strength or muscle-building supplement.

Lin Yi et al. 2023, Bagen Liao et al. 2021, Masashi Morifuji et al. 2024, Jimmy Wen et al. 2024

C

May produce a small reduction in diastolic blood pressure

Tier 1

A dedicated 2026 meta-analysis found a small average diastolic blood-pressure reduction and no significant overall systolic effect [9]. The effect is not large enough to treat NMN as an antihypertensive therapy.

Mu Zhang et al. 2026, Wenyu Yang et al. 2026

F

Extends human lifespan or reverses aging

Tier 4

Long-term mouse studies provide the geroscience rationale [21], but no human trial has shown lifespan extension or generalized age reversal. The broader 2026 systematic review found consistent NAD target engagement but heterogeneous clinical outcomes [11].

Kathryn F Mills et al. 2016, Cory Gallagher et al. 2026, Wenyu Yang et al. 2026

How it compares

DoNotAge Pure NMN SupplementRenue By Science Pure NMN Powder ProHealth NMN Pro 1000
Named NMN source Uthever® β-NMN No named Uthever-style source highlighted on current Pure Powder page Uthever® β-NMN
Unit / serving dose 500 mg per capsule or scoop; brand highlights 1,000 mg/day 500 mg per scoop; up to 500 mg twice daily in brand guidance 1,000 mg per serving
COA / finished-product testing transparency Every-batch testing stated; DoNotAge currently provides CoA access Public lot-matched potency and contaminant reports with archived batches COAs stated as available; every-batch third-party testing claimed
Named ingredient with published human RCT Yes — Uthever® 300 mg/day, 60 days Not identified on current Pure Powder page Yes — same Uthever® evidence base
Exact finished product clinically tested No No No
Formula simplicity Single active NMN Single active NMN powder Single active NMN capsules
Biohack Blueprint position #1 recommended NMN #2 — best public testing/value alternative #3 — credible ingredient, overextended marketing

Clinical pharmacology

DoNotAge gives 500 mg per capsule or scoop and highlights 1,000 mg/day. Human NMN research spans roughly 125–2,000 mg/day, with several meaningful signals at 250–300 mg/day. The published Uthever® trial used 300 mg/day, so a higher retail dose should be treated as a studied exposure—not as proof of proportionally greater benefit.

Dose tiers

TierDoseFrequencyDurationNotes
Lower clinical range 250–300 mg/day Daily 8–12 weeks in several key trials

This range produced clear human biological activity and includes important positive studies for insulin sensitivity, sleep/physical function and the 300 mg/day Uthever randomized trial. It shows that gram-level dosing is not required for NMN to be biologically active.
DoNotAge practical range 500–1,000 mg/day Daily Continuous daily use per brand guidance

Each DoNotAge capsule or scoop contains 500 mg. The brand highlights 1,000 mg/day; 1,000 mg/day has modern human pharmacokinetic data, but the published Uthever ingredient trial itself used 300 mg/day.
High research exposure 1,200–2,000 mg/day Daily Usually days to two weeks in specialized studies

High-dose protocols demonstrate substantial exposure and short-term tolerability in selected research settings. They have not established superior long-term health outcomes, so higher doses should not be treated as automatically better.

From bench to bedside

PathwayPreclinical findingHuman translationConfidence
NMN -> NAD+ target engagement NMN replenishes NAD-related pools across tissues in animal aging models and influences NAD-dependent metabolism. Strong: multiple human trials show increased blood NAD+ or related metabolites after oral NMN, including the Uthever trial and 2026 direct precursor comparisons. High
NAD+ restoration -> metabolic signaling Animal and cellular models connect NAD biology with insulin signaling, mitochondrial function and metabolic homeostasis. Partial: one strong prediabetes trial improved skeletal-muscle insulin sensitivity, but pooled fasting glucose, HbA1c and lipid outcomes are largely neutral. Moderate
NAD+ augmentation -> healthy aging / longevity Long-term NMN exposure improved several age-associated phenotypes in mice and supports a broader geroscience rationale. Unproven: human trials are too short and small to demonstrate lifespan extension, delayed major disease or generalized reversal of biological aging. Low

Drug interactions

High caution / specialist review

Active cytotoxic chemotherapy

Preclinical pancreatic-cancer research found NMN could increase NAD availability, reduce treatment-induced oxidative stress and protect tumor cells from several chemotherapies under experimental conditions.

Recommendation:

Do not self-add NMN during active cancer treatment. Discuss it with the treating oncology team, particularly with fluoropyrimidine, oxaliplatin or gemcitabine-based therapy. This concern is preclinical but directly relevant to treatment response.

Monitor

Glucose- or blood-pressure-lowering medication

NMN can influence insulin sensitivity and may modestly lower diastolic blood pressure in some human datasets, creating potential pharmacodynamic overlap even though a formal drug-metabolism interaction is not established.

Recommendation:

People using insulin, sulfonylureas or multiple antihypertensives should monitor the clinical variables already being treated and discuss meaningful changes with their clinician rather than assuming zero overlap.

Bioavailability tips

Standard oral NMN already raises NAD-related biomarkers in human studies, so a liposomal or sublingual system is not required for biological activity. DoNotAge suggests morning or early-afternoon use, but human timing evidence does not establish a universal best hour. Taking it consistently, with or without food according to tolerance, is more evidence-aligned than treating timing as a precise chronotherapy protocol.

Special populations

PopulationRecommendationRationale
Pregnancy or breastfeeding Avoid unless specifically advised by a clinician

Adequate human reproductive and developmental safety data are lacking. EFSA's 2026 assessed target population for a specified β-NMN material excluded pregnant and lactating women.
Active cancer or chemotherapy Oncology-team decision

NMN has not been shown to cause cancer in humans, but 2026 pancreatic-cancer models raise a treatment-specific concern that added NAD precursor could protect malignant cells under chemotherapy. Avoid routine self-supplementation during active treatment.
Advanced kidney or liver disease Use only with clinician oversight

Short-term trials are broadly reassuring, but advanced chronic organ disease is not well represented in ordinary NMN supplement studies. Polypharmacy and altered metabolism make these populations different from healthy trial participants.
Children and adolescents Not recommended for routine longevity use

The adult NMN evidence base does not establish a need, effective dose or long-term safety profile for children or adolescents.

Therapeutic positioning

DoNotAge earns our #1 overall NMN position by combining a named clinically studied β-NMN source with a simple formula, flexible capsule/powder dosing and strong quality-control documentation. Some competitors excel on one isolated dimension—such as Renue's highly granular public batch archive or Nutricost's low price—but DoNotAge gives us the strongest overall balance of evidence traceability, testing, usability and formulation simplicity.

Renue By Science Pure NMN Powder

Alternative DoNotAge preferred overall

Renue's biggest advantage is public lot-matched finished-product testing and very aggressive price per gram. DoNotAge's advantage is the explicitly named Uthever® source and the clearer ingredient-to-human-trial evidence chain. We rank DoNotAge first overall and Renue as the strongest testing-transparency alternative.

ProHealth NMN Pro 1000

Direct Uthever competitor DoNotAge preferred

ProHealth also uses Uthever® and supplies a high dose, but its current marketing leans harder on biological-age reversal and 'only clinically proven' language than the peer-reviewed evidence supports. DoNotAge earns the edge for simpler positioning and format flexibility.

Nutricost NMN

Budget alternative Nutricost for price; DoNotAge for evidence traceability

Nutricost is dramatically cheaper and states third-party testing by ISO-accredited laboratories. Its current public product page does not provide the same named clinically studied ingredient source or lot-level evidence chain we want from an evidence-first NMN product.

Wonderfeel Youngr

Multi-ingredient stack DoNotAge preferred for NMN-first use

Youngr combines 900 mg NMN with resveratrol, ergothioneine, hydroxytyrosol and vitamin D3. That may appeal to stack-seekers, but the finished formula lacks a randomized trial and makes attribution harder. DoNotAge is much easier to match to NMN-specific evidence.

NMN is an optional longevity intervention layered on top of sleep, exercise, nutrition, blood-pressure control, metabolic health and other fundamentals. No NMN supplement—including this one—has demonstrated human lifespan extension or replaces evidence-based medical care.

This product is not a substitute for prescribed treatment, cancer care, diabetes or blood-pressure medication, a balanced diet, exercise or evaluation of persistent fatigue and other symptoms.

About buying through us

Why is DoNotAge your #1 NMN recommendation?

It combines a simple single-ingredient formula, explicit Uthever® sourcing, straightforward 500 mg dosing, current CoA access and every-batch testing claims. That gives us the strongest overall balance of traceability, product simplicity, quality control and connection to the human Uthever® evidence base.

Does the Uthever trial mean this exact DoNotAge product is clinically proven?

No. The published Uthever randomized trial used 300 mg/day of the branded ingredient. DoNotAge's finished product and its highlighted 1,000 mg/day routine were not the exact product-dose combination tested in that trial.

Do I need 1,000 mg/day because DoNotAge recommends it?

No universal 1,000 mg requirement exists. Multiple human studies show biological activity and selected positive clinical signals at 250–300 mg/day. One gram is a studied exposure, not a proven superior dose for everyone.

Does DoNotAge provide a Certificate of Analysis for Pure NMN?

Yes. DoNotAge states that every batch is independently tested for purity and composition. Its March 2026 NMN guidance says the latest NMN CoA is available on its website, while the current Pure NMN product FAQ says purity certificates are available on request. In either case, the brand is explicitly offering CoA access rather than asking buyers to rely on an unsupported purity claim.

Why not choose Renue By Science instead?

Renue is a credible NMN alternative with its own testing and formulation strengths. We rank DoNotAge first because it explicitly uses Uthever® β-NMN, keeps the formula simple and gives a clear ingredient-level link to published human randomized evidence while maintaining current batch-testing and CoA-access claims.

Reader questions

Is DoNotAge NMN Uthever?

Yes. DoNotAge's current Pure NMN page states that it sources Uthever β-NMN from EffePharm.

How much NMN is in DoNotAge Pure NMN?

The current product page states 500 mg per capsule or scoop, with a recommended daily serving of 1,000 mg.

Is DoNotAge NMN third-party tested?

Yes. DoNotAge states that every batch is independently third-party tested for purity and potency to its 99.8% standard, and it provides NMN Certificate of Analysis documentation on its current site.

What purity does DoNotAge claim?

The company states that Pure NMN is tested to meet a 99.8% purity standard. Purity should still be distinguished from finished-product potency.

Does DoNotAge use clinically studied NMN?

Yes. DoNotAge uses Uthever® β-NMN, a named ingredient with a published randomized human trial. The retail product itself has not been separately tested as a finished formula, which is common across the NMN supplement category.

DoNotAge powder or capsules: which is better?

Neither format is proven clinically superior. Capsules provide easier dose consistency; powder offers flexible dosing and avoids capsule shells.

Does DoNotAge NMN need refrigeration?

DoNotAge currently says refrigeration is not required and recommends a cool, dry place away from sunlight and extreme heat.

Is 1,000 mg of DoNotAge NMN better than 300 or 500 mg?

Higher NMN doses can increase exposure, but a proportional improvement in health outcomes has not been demonstrated. Several positive human trials use 250–300 mg/day.

Editorial credibility

Portrait of Dr. Khaled Mahmoud, ICU physician and founder of Biohack Blueprint

Author

Dr. Khaled Mahmoud, MBBCh

MBBCh

Critical Care Medicine, Longevity Science & Editorial Direction

Portrait of Dr. Amr Yasser, cardiometabolic and musculoskeletal reviewer for Biohack Blueprint

Reviewer

Dr. Amr Yasser, PhD

MBBCh, PhD, General Surgery, Cardiometabolic Medicine, Musculoskeletal Research

Cardiometabolic, Musculoskeletal, Gut & Bioavailability

Portrait of Dr. Abdulla Mostafa, neuroscience reviewer for Biohack Blueprint

Reviewer

Dr. Abdulla Mostafa, PhD

MBBCh, PhD, Neuroscience, Neurosurgery

Cellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology

Our #1 NMN pick for 2026: Uthever® traceability, current CoA access, every-batch testing, simple filler-free formulation, flexible 500 mg dosing and a strong ingredient-to-human-research evidence chain.

Related reading

NMN Supplement: What It Is, How It Works & What Human Research Shows

NMN Benefits: What Human Trials and Meta-Analyses Actually Show

NMN Dosage: Human Doses From 100 mg to 2,000 mg Explained

NMN Side Effects & Safety: What Human Studies Actually Found

NMN vs NAD+: Are They the Same, and Which Has Better Evidence?

NMN vs NR: Two Head-to-Head Human Studies Compared (2026)

Is NMN Banned? US, EU, UK & Australia Status Explained

Liposomal NMN vs Capsules, Powder and Sublingual NMN

How and When to Take NMN: Morning, Night, Food, Fasting & Sublingual

NMN Human Trials: Published Clinical Evidence Mapped and Explained

How to Verify NMN Purity: COAs, Lab Tests, β-NMN & Label Accuracy

NMN and Resveratrol: Should You Take Them Together?

NMN Drug Interactions: Medications, Cancer Therapy & What We Actually Know

NMN for Weight Loss: Does It Burn Fat or Change Metabolism?

NMN for Skin: Anti-Aging, Pigmentation, Wrinkles & What the Evidence Shows

NMN for Hair Growth: Human Study, Hair Loss & Gray Hair Claims

NMN for Women: Menopause, Fertility, Metabolism, Hair & Safety

NMN for Men: Testosterone, Muscle, Energy, Fertility & Safety

NMN and Blood Pressure: What the 2026 Meta-Analysis Found

NMN and Diabetes: Insulin Sensitivity, Glucose & HbA1c Evidence

NMN for Muscle, Exercise & Physical Performance: Human Evidence

NMN for Sleep, Fatigue & Energy: What Human Trials Show

NMN and Cancer: Risk, Chemotherapy & Conflicting 2026 Evidence

NMN Foods: Natural Sources and How Much NMN They Actually Contain

How NMN Works: NAD+, the Salvage Pathway, Gut Microbiome & Human Pharmacology

Uthever NMN: Clinical Trial, Dose, Purity & What the Branded Ingredient Proves

David Sinclair and NMN in 2026: What He Actually Says He Takes—and What That Proves

NMN Reddit in 2026: 16 Common Claims Checked Against Human Research

Best NMN Supplements in 2026: 5 Products Compared by Evidence, Purity & Transparency

Where to Buy NMN in 2026: Direct, Amazon, iHerb & Retailer Safety

Why People Stop Taking NMN—and What Happens When You Stop
  1. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults Hao Huang (2022) . Frontiers in Aging Read on our Data CenterView on PubMed View on PMC DOI
  2. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Frézal A, Nazari A, Van den Abbeele P, Godin JP, Nutten S, Cuenoud B (2026) . Nature Metabolism Read on our Data CenterView on PubMed View on PMC DOI
  3. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis Wenyu Yang, Jun Huang, Zihan Tang, Cong Chen, Yanan Sun (2026) . Nutrients Read on our Data CenterView on PubMed View on PMC DOI
  4. Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim Sandalova E, Li H, Guan L, Raj SD, Lim TG, Tian E, Kennedy BK, Maier AB (2024) . GeroScience Read on our Data Center DOI
  5. Aqueous LC-MS/MS quantification of α-/β-nicotinamide mononucleotide in dietary supplements using a pentabromophenyl column Chng Sze Hoei, Nian-Hua Wu, Chao-Ming Tsen, Ping-Wei Sun, Han-Wei Chang, Shin-Yuan Wang, Hung-Yu Lin (2026) . Analytica Chimica Acta Read on our Data CenterView on PubMed DOI
  6. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects Keisuke Okabe, Keisuke Yaku, Yoshiaki Uchida, Yuichiro Fukamizu, Toshiya Sato, Takanobu Sakurai, Kazuyuki Tobe, Takashi Nakagawa (2022) . Frontiers in Nutrition Read on our Data CenterView on PubMed View on PMC DOI
  7. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial Lin Yi, Andrea B Maier, Rongsheng Tao, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar (2023) . GeroScience Read on our Data CenterView on PubMed View on PMC DOI
  8. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Mihoko Yoshino, Jun Yoshino, Brandon D. Kayser, Gary J. Patti, Michael P. Franczyk, Kathryn F. Mills, Miriam Sindelar, Terri Pietka, Bruce W. Patterson, Shin-Ichiro Imai, Samuel Klein (2021) . Science Read on our Data CenterView on PubMed View on PMC DOI
  9. Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Mu Zhang, Yingci Chen, Nan Jiang, Jingjing Zeng, Jianyun Zhang, Chenyang Wu, Yingying Liu, Zizheng Nie, Jun Yang, Shufen Han (2026) . Nutrients Read on our Data CenterView on PubMed View on PMC DOI
  10. Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials Jimmy Wen, Burhaan Syed, Solomon Kim, Mouhamad Shehabat, Ubaid Ansari, Daniel I Razick, Muzammil Akhtar, David Pai (2024) . Cureus Read on our Data CenterView on PubMed View on PMC DOI
  11. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence Cory Gallagher, Owoturo Oluwaseun Emmanuel (2026) . Ageing Research Reviews Read on our Data CenterView on PubMed DOI
  12. Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men Jun Wakabayashi, Seiichiro Higashi, Masashi Morifuji (2026) . Scientific Reports Read on our Data CenterView on PubMed View on PMC DOI
  13. Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance Faith Nakazzi, Mehrdad Zarei, Mariana Lopes, Hallie J Graor, William C Beegan, Eric Gu, Sakineh Rezaei, Peder J Lund, Jordan M Winter (2026) . Cancer Letters Read on our Data CenterView on PubMed DOI
  14. Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Margarita Aguilera-Gómez, Francesco Cubadda, Thomas Frenzel, Ursula Gundert-Remy, Francesca Marcon, Harry J McArdle, Monika Neuhäuser-Berthold, Miguel Prieto Maradona, Alexandros Siskos, Matthew Wright, Elisa Beneventi, Annamaria Rossi, Maura Magani, Karen Ildico Hirsch-Ernst (2026) . EFSA Journal Read on our Data CenterView on PubMed View on PMC DOI
  15. MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S (2023) . The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences Read on our Data CenterView on PubMed DOI
  16. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men Junichiro Irie, Emi Inagaki, Masataka Fujita, Hideaki Nakaya, Masanori Mitsuishi, Shintaro Yamaguchi, Kazuya Yamashita, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Hideyuki Okano, Yo-ichi Nabeshima, Shin-ichiro Imai, Masato Yasui, Kazuo Tsubota, Hiroshi Itoh (2020) . Endocrine Journal Read on our Data CenterView on PubMed DOI
  17. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women Yuichiro Fukamizu, Yoshiaki Uchida, Akari Shigekawa, Toshiya Sato, Hisayuki Kosaka, Takanobu Sakurai (2022) . Scientific Reports Read on our Data CenterView on PubMed View on PMC DOI
  18. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials Feng Chen, Disheng Zhou, Alice Pik-Shan Kong, Nga Ting Yim, Siyu Dai, Yu Nan Chen, Lai Ling Hui (2024) . Current Diabetes Reports Read on our Data CenterView on PubMed View on PMC DOI
  19. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study Bagen Liao, Yunlong Zhao, Dan Wang, Xiaowen Zhang, Xuanming Hao, Min Hu (2021) . Journal of the International Society of Sports Nutrition Read on our Data CenterView on PubMed View on PMC DOI
  20. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study Masashi Morifuji, Seiichiro Higashi, Shukuko Ebihara, Masashi Nagata (2024) . GeroScience Read on our Data CenterView on PubMed View on PMC DOI
  21. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice Kathryn F Mills, Shohei Yoshida, Liana R Stein, Alessia Grozio, Shunsuke Kubota, Yo Sasaki, Philip Redpath, Marie E Migaud, Rajendra S Apte, Koji Uchida, Jun Yoshino, Shin-Ichiro Imai (2016) . Cell Metabolism Read on our Data CenterView on PubMed View on PMC DOI

Ready to try DoNotAge Pure NMN Supplement?

Use code BB10 for 10% off on DoNotAge.

Shop DoNotAge Pure NMN Supplement on DoNotAge →

14-day money-back guarantee

First published 19 Sep 2026 · Last verified 21 Sep 2026